Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin in Recurrent, Platinum Resistant/Refractory Ovarian Cancer
NCT00005836Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Feb 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoint: Antitumor Activity (Response Rate). Started Feb 2000; status: completed.
02
Drugs
oxaliplatin
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00005836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005836.